CA2863388C - Materials and methods for treating diarrhea - Google Patents
Materials and methods for treating diarrhea Download PDFInfo
- Publication number
- CA2863388C CA2863388C CA2863388A CA2863388A CA2863388C CA 2863388 C CA2863388 C CA 2863388C CA 2863388 A CA2863388 A CA 2863388A CA 2863388 A CA2863388 A CA 2863388A CA 2863388 C CA2863388 C CA 2863388C
- Authority
- CA
- Canada
- Prior art keywords
- glucose
- composition
- diarrhea
- secretion
- free
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010012735 Diarrhoea Diseases 0.000 title claims abstract description 71
- 238000000034 method Methods 0.000 title abstract description 13
- 239000000463 material Substances 0.000 title description 4
- 239000008103 glucose Substances 0.000 claims abstract description 209
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 206
- 239000000203 mixture Substances 0.000 claims abstract description 107
- 239000003792 electrolyte Substances 0.000 claims abstract description 22
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 19
- 108091052347 Glucose transporter family Proteins 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 229940024606 amino acid Drugs 0.000 claims description 19
- 235000001014 amino acid Nutrition 0.000 claims description 19
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 239000000758 substrate Substances 0.000 claims description 19
- 150000001720 carbohydrates Chemical class 0.000 claims description 14
- 241000702670 Rotavirus Species 0.000 claims description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 11
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 11
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 10
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 9
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 8
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 7
- 239000004472 Lysine Substances 0.000 claims description 7
- 239000004473 Threonine Substances 0.000 claims description 7
- 229960000310 isoleucine Drugs 0.000 claims description 7
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 claims description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 6
- 235000003704 aspartic acid Nutrition 0.000 claims description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 6
- 150000002303 glucose derivatives Chemical class 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 5
- 241000282414 Homo sapiens Species 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 5
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 5
- 239000004474 valine Substances 0.000 claims description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
- RMTFNDVZYPHUEF-XZBKPIIZSA-N 3-O-methyl-D-glucose Chemical compound O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO RMTFNDVZYPHUEF-XZBKPIIZSA-N 0.000 claims description 3
- 210000000813 small intestine Anatomy 0.000 abstract description 39
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract description 13
- 206010014418 Electrolyte imbalance Diseases 0.000 abstract description 11
- 206010017943 Gastrointestinal conditions Diseases 0.000 abstract description 11
- 206010051283 Fluid imbalance Diseases 0.000 abstract description 9
- 229960001031 glucose Drugs 0.000 description 210
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 205
- 230000028327 secretion Effects 0.000 description 84
- 210000004027 cell Anatomy 0.000 description 55
- 230000003834 intracellular effect Effects 0.000 description 46
- 238000010521 absorption reaction Methods 0.000 description 33
- 210000001519 tissue Anatomy 0.000 description 32
- 239000011734 sodium Substances 0.000 description 28
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 25
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 25
- 230000001404 mediated effect Effects 0.000 description 24
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 description 23
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 description 23
- 230000000694 effects Effects 0.000 description 20
- 150000001450 anions Chemical class 0.000 description 16
- 238000011534 incubation Methods 0.000 description 16
- 239000004615 ingredient Substances 0.000 description 16
- 230000001419 dependent effect Effects 0.000 description 15
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 14
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 14
- 102000042092 Glucose transporter family Human genes 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 229910001415 sodium ion Inorganic materials 0.000 description 14
- ZKZXNDJNWUTGDK-NSCUHMNNSA-N (E)-N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide Chemical compound C1=CC(Br)=CC=C1\C=C\CNCCNS(=O)(=O)C1=CC=CC2=CN=CC=C12 ZKZXNDJNWUTGDK-NSCUHMNNSA-N 0.000 description 13
- 230000004907 flux Effects 0.000 description 13
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 12
- 239000011575 calcium Substances 0.000 description 12
- 229910052791 calcium Inorganic materials 0.000 description 12
- 235000014633 carbohydrates Nutrition 0.000 description 12
- 229910052708 sodium Inorganic materials 0.000 description 12
- 108091006515 Anion channels Proteins 0.000 description 11
- 102000037829 Anion channels Human genes 0.000 description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 11
- 230000006377 glucose transport Effects 0.000 description 11
- 230000000968 intestinal effect Effects 0.000 description 11
- 229940077731 carbohydrate nutrients Drugs 0.000 description 10
- 210000001100 crypt cell Anatomy 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 210000003405 ileum Anatomy 0.000 description 10
- 210000004877 mucosa Anatomy 0.000 description 10
- 108010062745 Chloride Channels Proteins 0.000 description 9
- 108091006277 SLC5A1 Proteins 0.000 description 9
- 102000058090 Sodium-Glucose Transporter 1 Human genes 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 102000011045 Chloride Channels Human genes 0.000 description 8
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 8
- 108091006649 SLC9A3 Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 210000002919 epithelial cell Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 230000010355 oscillation Effects 0.000 description 8
- 230000003248 secreting effect Effects 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 7
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 7
- 108010038807 Oligopeptides Proteins 0.000 description 7
- 102000015636 Oligopeptides Human genes 0.000 description 7
- 102100030375 Sodium/hydrogen exchanger 3 Human genes 0.000 description 7
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000013355 food flavoring agent Nutrition 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 150000002482 oligosaccharides Polymers 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 230000032258 transport Effects 0.000 description 7
- WBSMIPAMAXNXFS-UHFFFAOYSA-N 5-Nitro-2-(3-phenylpropylamino)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCCC1=CC=CC=C1 WBSMIPAMAXNXFS-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 229960005261 aspartic acid Drugs 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000003086 colorant Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 229960004441 tyrosine Drugs 0.000 description 6
- 229960004295 valine Drugs 0.000 description 6
- NLMDJJTUQPXZFG-UHFFFAOYSA-N 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane Chemical compound C1COCCOCCNCCOCCOCCN1 NLMDJJTUQPXZFG-UHFFFAOYSA-N 0.000 description 5
- YJIYWYAMZFVECX-UHFFFAOYSA-N 2-[N-[2-(acetyloxymethoxy)-2-oxoethyl]-2-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]anilino]acetic acid acetyloxymethyl ester Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O YJIYWYAMZFVECX-UHFFFAOYSA-N 0.000 description 5
- 102000003787 Anoctamin-1 Human genes 0.000 description 5
- 108090000160 Anoctamin-1 Proteins 0.000 description 5
- 208000004232 Enteritis Diseases 0.000 description 5
- 229940126902 Phlorizin Drugs 0.000 description 5
- 206010067470 Rotavirus infection Diseases 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000001142 anti-diarrhea Effects 0.000 description 5
- 239000006172 buffering agent Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000004153 glucose metabolism Effects 0.000 description 5
- 229960003646 lysine Drugs 0.000 description 5
- 210000000110 microvilli Anatomy 0.000 description 5
- IOUVKUPGCMBWBT-UHFFFAOYSA-N phloridzosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-UHFFFAOYSA-N 0.000 description 5
- IOUVKUPGCMBWBT-GHRYLNIYSA-N phlorizin Chemical compound O[C@@H]1[C@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-GHRYLNIYSA-N 0.000 description 5
- 235000019139 phlorizin Nutrition 0.000 description 5
- 229940043437 protein kinase A inhibitor Drugs 0.000 description 5
- 201000009881 secretory diarrhea Diseases 0.000 description 5
- 229960001153 serine Drugs 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 229960002898 threonine Drugs 0.000 description 5
- YSCNMFDFYJUPEF-OWOJBTEDSA-N 4,4'-diisothiocyano-trans-stilbene-2,2'-disulfonic acid Chemical compound OS(=O)(=O)C1=CC(N=C=S)=CC=C1\C=C\C1=CC=C(N=C=S)C=C1S(O)(=O)=O YSCNMFDFYJUPEF-OWOJBTEDSA-N 0.000 description 4
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 4
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- -1 calcium-activated chloride Chemical class 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 210000001842 enterocyte Anatomy 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000012656 protein kinase A inhibitor Substances 0.000 description 4
- 108010065251 protein kinase modulator Proteins 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 201000009840 acute diarrhea Diseases 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000000741 diarrhetic effect Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000147 enterotoxin Substances 0.000 description 3
- 231100000655 enterotoxin Toxicity 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229960002449 glycine Drugs 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000007790 scraping Methods 0.000 description 3
- 229960004799 tryptophan Drugs 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 102000034534 Cotransporters Human genes 0.000 description 2
- 108020003264 Cotransporters Proteins 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
- 101710146739 Enterotoxin Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
- 235000019766 L-Lysine Nutrition 0.000 description 2
- 229930182844 L-isoleucine Natural products 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102100037202 Sodium/myo-inositol cotransporter 2 Human genes 0.000 description 2
- 101710090560 Sodium/myo-inositol cotransporter 2 Proteins 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000003287 bathing Methods 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 2
- 229960004484 carbachol Drugs 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 229960002433 cysteine Drugs 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000011902 gastrointestinal surgery Methods 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- 230000037427 ion transport Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 238000000853 optical rotatory dispersion Methods 0.000 description 2
- 101150030907 ord gene Proteins 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000029054 response to nutrient Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004016 Bacterial diarrhoea Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 101100378191 Caenorhabditis elegans aco-2 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 108010086832 Chloride-Bicarbonate Antiporters Proteins 0.000 description 1
- 102000006786 Chloride-Bicarbonate Antiporters Human genes 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 241000223935 Cryptosporidium Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 241000289427 Didelphidae Species 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 1
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 1
- 241000224467 Giardia intestinalis Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001125417 Homo sapiens Na(+)/H(+) exchange regulatory cofactor NHE-RF3 Proteins 0.000 description 1
- 101000716688 Homo sapiens Sodium/glucose cotransporter 1 Proteins 0.000 description 1
- 241000617996 Human rotavirus Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229920005479 Lucite® Polymers 0.000 description 1
- 102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 description 1
- 108010041955 MAP-kinase-activated kinase 2 Proteins 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100029448 Na(+)/H(+) exchange regulatory cofactor NHE-RF2 Human genes 0.000 description 1
- 102100029467 Na(+)/H(+) exchange regulatory cofactor NHE-RF3 Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710195254 Non-structural glycoprotein Proteins 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000037065 SLC5 Human genes 0.000 description 1
- 108091006210 SLC5 Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000032384 Severe immune-mediated enteropathy Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 101150031256 Slc9a3r2 gene Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 102000046061 Sodium-Hydrogen Exchanger 3 Human genes 0.000 description 1
- 102000052126 Sodium-Hydrogen Exchangers Human genes 0.000 description 1
- 108091006672 Sodium–hydrogen antiporter Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- BKYHTWFRZPRHNM-UHFFFAOYSA-N acetyloxymethyl 2-[n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-[3-(acetyloxymethoxy)-6-oxoxanthen-9-yl]-2-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]anilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=CC=C1OCCOC1=CC(C2=C3C=CC(=O)C=C3OC3=CC(OCOC(C)=O)=CC=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O BKYHTWFRZPRHNM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000001974 autoimmune enteropathy Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000013262 cAMP assay Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000000064 cholinergic agonist Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 210000004921 distal colon Anatomy 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000008846 dynamic interplay Effects 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 239000002713 epithelial sodium channel blocking agent Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 229940085435 giardia lamblia Drugs 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 102000052194 human SLC5A1 Human genes 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000004495 interstitial cells of cajal Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 210000004937 luminal membrane Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000021962 pH elevation Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000002661 proton therapy Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000310 rehydration solution Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 108700015434 rotavirus NS28 Proteins 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 102000003137 synaptotagmin Human genes 0.000 description 1
- 108060008004 synaptotagmin Proteins 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261596480P | 2012-02-08 | 2012-02-08 | |
| US61/596,480 | 2012-02-08 | ||
| PCT/US2013/025294 WO2013119917A1 (en) | 2012-02-08 | 2013-02-08 | Materials and methods for treating diarrhea |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2863388A1 CA2863388A1 (en) | 2013-08-15 |
| CA2863388C true CA2863388C (en) | 2020-11-17 |
Family
ID=48948047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2863388A Active CA2863388C (en) | 2012-02-08 | 2013-02-08 | Materials and methods for treating diarrhea |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20140377374A1 (en:Method) |
| EP (1) | EP2812007B1 (en:Method) |
| JP (1) | JP6084238B2 (en:Method) |
| KR (2) | KR102262179B1 (en:Method) |
| CN (1) | CN104093410B (en:Method) |
| AP (1) | AP3941A (en:Method) |
| AU (1) | AU2013216871B2 (en:Method) |
| BR (1) | BR112014019350B1 (en:Method) |
| CA (1) | CA2863388C (en:Method) |
| EA (1) | EA034014B1 (en:Method) |
| ES (1) | ES2862392T3 (en:Method) |
| HK (1) | HK1204290A1 (en:Method) |
| IN (1) | IN2014DN06737A (en:Method) |
| MX (1) | MX368543B (en:Method) |
| WO (1) | WO2013119917A1 (en:Method) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103153298B (zh) | 2010-09-24 | 2015-11-25 | 佛罗里达大学研究基金会有限公司 | 用于改善胃肠功能的材料和方法 |
| BR112015021931A8 (pt) | 2013-03-11 | 2018-01-23 | Univ Florida | usos de composições farmacêuticas para prevenção e/ou tratamento de complicações do pulmão induzidas por radiação e da função pulmonar |
| CN107106527B (zh) * | 2014-11-24 | 2020-11-24 | 恩特林斯科健康解决方案股份公司 | 用于治疗疾病症状的氨基酸组合物 |
| CA3135553C (en) | 2016-10-04 | 2024-05-21 | University Of Florida Research Foundation, Incorporated | Amino acid compositions and uses thereof |
| WO2019070753A1 (en) * | 2017-10-02 | 2019-04-11 | University Of Florida Research Foundation, Incorporated | AMINO ACID COMPOSITIONS AND METHODS FOR TREATING DIARRHEA |
| JP2023531874A (ja) * | 2020-06-02 | 2023-07-26 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド | 下痢を治療するための製剤および方法 |
| CN116194136A (zh) | 2020-07-02 | 2023-05-30 | 佛罗里达大学研究基金会公司 | 用于促进水化的制剂及其使用方法 |
| CN118369093A (zh) * | 2021-05-28 | 2024-07-19 | 可口可乐公司 | 氨基酸水合配制品及使用方法 |
| CN115531363B (zh) * | 2021-06-30 | 2024-03-29 | 中国科学技术大学 | 预防、抑制或治疗轮状病毒感染的药物组合物及其用途 |
| US11878073B1 (en) | 2022-09-20 | 2024-01-23 | Entrinsic, LLC | Generation of hydration-targeted formulations and methods of use therein |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5290538A (en) * | 1988-12-22 | 1994-03-01 | Skrezek Christian | Nephro protective infusion solutions |
| JP3301646B2 (ja) * | 1993-03-19 | 2002-07-15 | シスメックス株式会社 | 幼若細胞測定用試薬 |
| ATE287703T1 (de) * | 1995-04-14 | 2005-02-15 | Nektar Therapeutics | Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit |
| JP4255656B2 (ja) * | 2001-09-17 | 2009-04-15 | 株式会社メニコン | 眼科用液剤及びコンタクトレンズ用液剤 |
| US20030143293A1 (en) * | 2002-01-31 | 2003-07-31 | Sergei Shushunov | Compositions and methods for treating diarrhea |
| JP2004123642A (ja) * | 2002-10-04 | 2004-04-22 | Shimizu Pharmaceutical Co Ltd | 電解質組成物 |
| DK175877B1 (da) * | 2002-11-11 | 2005-05-09 | Pharmalett As | Præparater til anvendelse som terapeutisk middel |
| US20050100637A1 (en) * | 2003-11-12 | 2005-05-12 | Robert Murray | Carbohydrate and electrolyte replacement composition |
| GB0503337D0 (en) * | 2005-02-17 | 2005-03-23 | Glaxosmithkline Biolog Sa | Compositions |
| JP4811576B2 (ja) * | 2005-03-31 | 2011-11-09 | 味の素株式会社 | 水分電解質補給飲料 |
| JP4512013B2 (ja) * | 2005-09-07 | 2010-07-28 | 和光堂株式会社 | 液体飲料組成物及びその製造方法 |
| DE102006018293A1 (de) * | 2006-04-20 | 2007-10-25 | Fresenius Kabi Deutschland Gmbh | Pädiatrische Aminosäurelösung zur parenteralen Ernäherung |
| CN103153298B (zh) * | 2010-09-24 | 2015-11-25 | 佛罗里达大学研究基金会有限公司 | 用于改善胃肠功能的材料和方法 |
| BR112015021931A8 (pt) * | 2013-03-11 | 2018-01-23 | Univ Florida | usos de composições farmacêuticas para prevenção e/ou tratamento de complicações do pulmão induzidas por radiação e da função pulmonar |
-
2013
- 2013-02-08 US US14/376,027 patent/US20140377374A1/en not_active Abandoned
- 2013-02-08 WO PCT/US2013/025294 patent/WO2013119917A1/en not_active Ceased
- 2013-02-08 EP EP13747028.2A patent/EP2812007B1/en active Active
- 2013-02-08 MX MX2014009557A patent/MX368543B/es active IP Right Grant
- 2013-02-08 BR BR112014019350-9A patent/BR112014019350B1/pt active IP Right Grant
- 2013-02-08 IN IN6737DEN2014 patent/IN2014DN06737A/en unknown
- 2013-02-08 KR KR1020207024016A patent/KR102262179B1/ko active Active
- 2013-02-08 CN CN201380008424.6A patent/CN104093410B/zh active Active
- 2013-02-08 EA EA201400827A patent/EA034014B1/ru not_active IP Right Cessation
- 2013-02-08 AP AP2014007916A patent/AP3941A/en active
- 2013-02-08 JP JP2014556712A patent/JP6084238B2/ja active Active
- 2013-02-08 AU AU2013216871A patent/AU2013216871B2/en active Active
- 2013-02-08 CA CA2863388A patent/CA2863388C/en active Active
- 2013-02-08 ES ES13747028T patent/ES2862392T3/es active Active
- 2013-02-08 HK HK15104949.7A patent/HK1204290A1/xx unknown
- 2013-02-08 KR KR1020147025066A patent/KR20140120941A/ko not_active Ceased
-
2015
- 2015-06-04 US US14/730,974 patent/US20150297636A1/en not_active Abandoned
-
2020
- 2020-07-31 US US16/945,040 patent/US20210299076A1/en not_active Abandoned
-
2024
- 2024-11-14 US US18/947,836 patent/US20250073260A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2812007B1 (en) | 2020-12-30 |
| US20210299076A1 (en) | 2021-09-30 |
| BR112014019350A8 (pt) | 2017-07-11 |
| CN104093410A (zh) | 2014-10-08 |
| BR112014019350B1 (pt) | 2020-09-24 |
| BR112014019350A2 (en:Method) | 2017-06-20 |
| EP2812007A4 (en) | 2015-09-09 |
| US20140377374A1 (en) | 2014-12-25 |
| EP2812007A1 (en) | 2014-12-17 |
| JP6084238B2 (ja) | 2017-02-22 |
| EA201400827A1 (ru) | 2014-12-30 |
| CA2863388A1 (en) | 2013-08-15 |
| MX368543B (es) | 2019-10-07 |
| KR102262179B1 (ko) | 2021-06-07 |
| AP2014007916A0 (en) | 2014-09-30 |
| US20150297636A1 (en) | 2015-10-22 |
| AU2013216871A1 (en) | 2014-09-11 |
| AU2013216871B2 (en) | 2017-08-17 |
| KR20200105525A (ko) | 2020-09-07 |
| HK1204290A1 (en) | 2015-11-13 |
| ES2862392T3 (es) | 2021-10-07 |
| AP3941A (en) | 2016-12-16 |
| KR20140120941A (ko) | 2014-10-14 |
| IN2014DN06737A (en:Method) | 2015-05-22 |
| US20250073260A1 (en) | 2025-03-06 |
| WO2013119917A1 (en) | 2013-08-15 |
| CN104093410B (zh) | 2018-04-27 |
| EA034014B1 (ru) | 2019-12-19 |
| MX2014009557A (es) | 2014-11-10 |
| JP2015506981A (ja) | 2015-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250073260A1 (en) | Amino acid formulations and uses thereof | |
| US20250248972A1 (en) | Materials and methods for improving gastrointestinal function | |
| TWI775921B (zh) | 用於治療和高血氨症或肌肉耗損中之一者或兩者相關之肝疾病及失調之組合物及方法 | |
| PT2214480E (pt) | Métodos de tratamento de esteato-hepatite não alcoólica (nash) utilizando produtos de cisteamina | |
| Tang et al. | T1739 Selective Regulation of Na+-K+-2cl− Cotransporter Surface Expression and Epithelial Cl− Secretion By Novel Protein Kinase C (PKC) Isoforms δ and ɛ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180110 |